Iambic Therapeutics, Inc. Common Stock (IAM) FinancialsIAMIambic Therapeutics, Inc. Common Stock

In the context of the broader market, IAM competes directly with industry leaders such as PRME and SANA. With a market capitalization of $663.61M, it holds a significant position in the sector. When comparing efficiency, IAM's gross margin of N/A stands against PRME's 100.00% and SANA's N/A. Such benchmarking helps identify whether Iambic Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company shows no earnings with a P/E ratio of 0 and a forward P/E of 0, indicating it is not generating profits. Its price-to-sales ratio is quite high at 38.1, which raises concerns about valuation.